Ask a Question

Prefer a chat interface with context about you and your work?

Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group

Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group

Loss of power and clear description of treatment differences are key issues in designing and analyzing a clinical trial where nonproportional hazard (NPH) is a possibility. A log-rank test may be inefficient and interpretation of the hazard ratio estimated using Cox regression is potentially problematic. In this case, the current …